# EDGAR Filing Document

**Accession Number:** 0001650648
**File Stem:** 0001193125-26-114200
**Filing Date:** 2026-3
**Character Count:** 23148
**Document Hash:** 3d37f8dfc506c4cda70adc54daaa29ff
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-114200.hdr.sgml**: 20260318

**ACCESSION NUMBER**: 0001193125-26-114200

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**EFFECTIVENESS DATE**: 20260318

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 4D Molecular Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001650648
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473506994
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294420
- **FILM NUMBER:** 26770103

**BUSINESS ADDRESS:**
- **STREET 1:** 5858 HORTON STREET #455
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
- **BUSINESS PHONE:** 5105052680

**MAIL ADDRESS:**
- **STREET 1:** 5858 HORTON STREET #455
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 4D Molecular Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20200506

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 4D Molecular Therapeutics Inc
- **DATE OF NAME CHANGE:** 20150811

**As filed with the Securities and Exchange Commission on March 18, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## 4D Molecular Therapeutics, Inc.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **47-3506994** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **5858 Horton Street #455**<br> **Emeryville, California 94608**<br> **(510) 505-2680** | **94608** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**2020 Incentive Award Plan** 

**2020 Employee Stock Purchase Plan** 

**2025 Employment Inducement Award Plan** 

**(Full title of the plan)** 

**David Kirn, M.D.** 

**President and Chief Executive Officer** 

**4D Molecular Therapeutics, Inc.** 

**5858 Horton Street #455** 

**Emeryville, California 94608** 

**(Name and address of agent for service)** 

**(510) 505-2680**

**(Telephone number, including area code, of agent for service)** 

***Copies to:***

**Mark V. Roeder, Esq.** 

**John C. Williams, Esq.** 

**Latham & Watkins LLP** 

**140 Scott Drive** 

**Menlo Park, CA 94025** 

**(650) 328-4600**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

This Registration Statement on Form S-8 is being filed by 4D Molecular Therapeutics, Inc. (the "Registrant") for the purpose of registering (1) an additional 2,880,394 shares of the Registrant's common stock, par value $0.0001 per share (the "Common Stock"), issuable under the 2020 Incentive Award Plan as a result of the operation of an automatic annual increase provision therein, (2) an additional 576,079 shares of the Registrant's Common Stock, issuable under the 2020 Employee Stock Purchase Plan pursuant to the annual increase provision therein, and (3) an additional 1,000,000 shares of the Registrant's Common Stock that may be offered or issued pursuant to the Registrant's 2025 Employment Inducement Award Plan, as amended.

**INCORPORATION BY REFERENCE OF CONTENTS OF** 

**REGISTRATION STATEMENT ON FORM S-8** 

Pursuant to General Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the "SEC") on December 15, 2020 (File No. [333-251370](http://www.sec.gov/Archives/edgar/data/1650648/000119312520318232/d28592ds8.htm)), March 25, 2021 (File No. [333-254701](http://www.sec.gov/Archives/edgar/data/1650648/000119312521094535/d117615ds8.htm)), March 28, 2022 (File No. [333-263908](http://www.sec.gov/Archives/edgar/data/1650648/000119312522086836/d339775ds8.htm)), March 15, 2023, as amended on May 4, 2023 (File No. [333-270566](http://www.sec.gov/Archives/edgar/data/1650648/000119312523134747/d171989ds8pos.htm)), February 29, 2024 (File No. [333-277547](http://www.sec.gov/Archives/edgar/data/1650648/000119312524053647/d778402ds8.htm)), February 28, 2025 (File No. [333-285456](http://www.sec.gov/Archives/edgar/data/1650648/000119312525042758/d841501ds8.htm)) and May 8, 2025 (File No. [333-287089](http://www.sec.gov/Archives/edgar/data/1650648/000119312525116018/d944659ds8.htm)) are incorporated by reference herein.

**PART II** 

**Item 8. Exhibits.** 

**EXHIBIT INDEX** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| **Exhibit**<br> **Number** | <br>**Description** | **Form** | **Exhibit** | **Date Filed** | <br>**Filed**<br> **Herewith** |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Amended and Restated Certificate of Incorporation of 4D Molecular Therapeutics, Inc.](http://www.sec.gov/Archives/edgar/data/1650648/000119312520318186/d13863dex31.htm) | 8-K | 3.1 | 12/15/2020 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Amended and Restated Bylaws of 4D Molecular Therapeutics, Inc.](http://www.sec.gov/Archives/edgar/data/1650648/000119312525228289/fdmt-ex3_1.htm) | 8-K | 3.1 | 10/2/2025 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Form of Common Stock Certificate.](http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex42.htm) | S-1/A | 4.2 | 12/07/2020 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;4.4 | [Form of Pre-Funded Warrant issued in conjunction with February 2024 offering.](http://www.sec.gov/Archives/edgar/data/1650648/000119312524030203/d185041dex41.htm) | 8-K | 4.1 | 2/9/2024 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;4.5 | [Form of Pre-Funded Warrant issued in conjunction with November 2024 exchange.](http://www.sec.gov/Archives/edgar/data/1650648/000095017024126370/fdmt-ex4_4.htm) | 10-Q | 4.4 | 11/13/2024 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;4.6 | [Form of Pre-Funded Warrant issued in conjunction with December 2024 exchange.](http://www.sec.gov/Archives/edgar/data/1650648/000095017024135381/fdmt-ex4_1.htm) | 8-K | 4.1 | 12/11/2024 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;4.7 | [Form of Pre-Funded Warrant issued in conjunction with November 2025 offering.](http://www.sec.gov/Archives/edgar/data/1650648/000119312525272286/d89818dex41.htm) | 8-K | 4.1 | 11/7/2025 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;4.8 | [Form of Pre-Funded Warrant issued in conjunction with January 2026 exchange.](http://www.sec.gov/Archives/edgar/data/1650648/000119312526022559/fdmt-ex4_1.htm) | 8-K | 4.1 | 1/26/2026 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1 | [Opinion of Latham & Watkins LLP.](d88128dex51.htm) |  |  |  | X |
| 23.1 | [Consent of Latham & Watkins LLP (included in Exhibit 5.1).](d88128dex51.htm) |  |  |  | X |
| 23.2 | [Consent of Independent Registered Public Accounting Firm.](d88128dex232.htm) |  |  |  | X |
| 24.1 | [Power of Attorney (included in the signature page to this registration statement).](#sig) |  |  |  | X |
| 99.1(a)# | [4D Molecular Therapeutics, Inc. 2020 Incentive Award Plan.](http://www.sec.gov/Archives/edgar/data/0001650648/000119312520318232/d28592dex992a.htm) | S-8 | 99.2(a) | 12/15/2020 |  |
| 99.1(b)# | [Form of Stock Option Grant Notice and Stock Option Agreement under the 2020 Incentive Award Plan.](http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex102b.htm) | S-1/A | 10.2(b) | 12/07/2020 |  |
| 99.1(c)# | [Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2020 Incentive Award Plan.](http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex102c.htm) | S-1/A | 10.2(c) | 12/07/2020 |  |
| 99.1(d)# | [Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2020 Incentive Award Plan.](http://www.sec.gov/Archives/edgar/data/1650648/000119312520311111/d69563dex102d.htm) | S-1/A | 10.2(d) | 12/07/2020 |  |
| 99.2# | [4D Molecular Therapeutics, Inc. 2020 Employee Stock Purchase Plan.](http://www.sec.gov/Archives/edgar/data/0001650648/000119312520318232/d28592dex993.htm) | S-8 | 99.3 | 12/15/2020 |  |
| 99.3(a)# | [4D Molecular Therapeutics, Inc. 2025 Employment Inducement Award Plan.](http://www.sec.gov/Archives/edgar/data/1650648/000095017025030056/fdmt-ex10_19.htm) | 10-K | 10.19 | 2/28/2025 |  |
| 99.3(b)# | [Amendment to 4D Molecular Therapeutics, Inc. 2025 Employment Inducement Award Plan.](http://www.sec.gov/Archives/edgar/data/1650648/000119312526114075/fdmt-ex10_16.htm) | 10-K | 10.16 | 3/18/2026 |  |
| 99.3(c)# | [Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2025 Employment Inducement Award Plan.](http://www.sec.gov/Archives/edgar/data/1650648/000095017025030056/fdmt-ex10_20.htm) | 10-K | 10.20 | 2/28/2025 |  |
| 99.3(d)# | [Form of Stock Option Grant Notice and Stock Option Agreement under the 2025 Employment Inducement Award Plan.](http://www.sec.gov/Archives/edgar/data/1650648/000095017025030056/fdmt-ex10_21.htm) | 10-K | 10.21 | 2/28/2025 |  |
| 107.1 | [Calculation of Filing Fee Table.](d88128dexfilingfees.htm) |  |  |  | X |

---

# Indicates management contract or compensatory plan.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California, on March 18, 2026.

---

| | |
|:---|:---|
| **4D Molecular Therapeutics, Inc.** | **4D Molecular Therapeutics, Inc.** |
| By: | /s/ Kristian Humer |
|  | Kristian Humer |
|  | Chief Financial Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David Kirn, M.D. and Kristian Humer, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement, including post-effective amendments or any abbreviated registration statement and any amendments thereto filed, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ David Kirn | President, Chief Executive Officer and Director | March 18, 2026 |
| **David Kirn, M.D.** | *(Principal Executive Officer)* |  |
| /s/ Kristian Humer | Chief Financial Officer | March 18, 2026 |
| **Kristian Humer** | *(Principal Financial Officer)* |  |
| /s/ Ashoo Gupta | Vice President, Finance and Controller | March 18, 2026 |
| **Ashoo Gupta** | *(Principal Accounting Officer)* |  |
| /s/ John F. Milligan | Executive Chairman | March 18, 2026 |
| **John F. Milligan, Ph.D.** |  |  |
| /s/ Jacob Chacko | Director | March 18, 2026 |
| **Jacob Chacko, M.D., MBA** |  |  |
| /s/ Susannah Gray | Director | March 18, 2026 |
| **Susannah Gray, MBA** |  |  |
| /s/ Nancy Miller-Rich | Director | March 18, 2026 |
| **Nancy Miller-Rich** |  |  |
| /s/ Glenn Sblendorio | Director | March 18, 2026 |
| **Glenn Sblendorio** |  |  |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Charles P. Theuer | Director | March 18, 2026 |
| **Charles P. Theuer, M.D., Ph.D.** |  |  |
| /s/ Shawn Cline Tomasello | Director | March 18, 2026 |
| **Shawn Cline Tomasello, MBA** |  |  |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | | |
|:---|:---|:---|
|  | 140 Scott Drive | 140 Scott Drive |
|  | Menlo Park, California 94025 | Menlo Park, California 94025 |
|  | Tel: +1.650.328.4600 Fax: +1.650.463.2600 | Tel: +1.650.328.4600 Fax: +1.650.463.2600 |
|  | www.lw.com |  |
| ![LOGO](g88128dsp6.jpg) | FIRM / AFFILIATE OFFICES | FIRM / AFFILIATE OFFICES |
| ![LOGO](g88128dsp6.jpg) | Austin | Milan |
| ![LOGO](g88128dsp6.jpg) | Beijing | Munich |
| ![LOGO](g88128dsp6.jpg) | Boston | New York |
|  | Brussels | Orange County |
|  | Chicago | Paris |
|  | Dubai | Riyadh |
|  | Düsseldorf | San Diego |
|  | Frankfurt | San Francisco |
|  | Hamburg | Seoul |
|  | Hong Kong | Silicon Valley |
|  | Houston | Singapore |
|  | London | Tel Aviv |
|  | Los Angeles | Tokyo |
|  | Madrid | Washington, D.C. |

---

March 18, 2026

4D Molecular Therapeutics, Inc.

5858 Horton Street #455

Emeryville, California 94608

---

| | |
|:---|:---|
| Re: | Registration Statement on Form S-8; 4,456,473 shares of Common Stock, par value $0.0001 per share  |

---

To the addressee set forth above:

We have acted as special counsel to 4D Molecular Therapeutics, Inc., a Delaware corporation (the "***Company***"), in connection with the registration by the Company of an aggregate of 4,456,473 shares of Common Stock of the Company, par value $0.0001 per share (the "***Shares***"), issuable under the Company's 2020 Incentive Award Plan (the "***2020 Plan***"), the 2020 Employee Stock Purchase Plan (the "***ESPP***") and the 2025 Employment Inducement Award Plan (the "***Inducement Plan***" and together with the 2020 Plan and ESPP, the "***Plans***"). The Shares are included in a registration statement on Form S-8 under the Securities Act of 1933, as amended (the "***Act***"), filed with the Securities and Exchange Commission (the "***Commission***") on March 18, 2026 (the "***Registration Statement***"). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the related prospectus, other than as expressly stated herein with respect to the issuance of the Shares.

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware, and we express no opinion with respect to any other laws.

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company for legal consideration in excess of par value in the circumstances contemplated by the Plans, assuming in each case that the individual issuances, grants or awards under the Plans are duly authorized by all necessary corporate action and duly issued, granted or awarded and

------

**March 18, 2026** 

**Page 2**![LOGO](g88128g0317133226613.jpg)

exercised in accordance with the requirements of law and the Plans (and the agreements and awards duly adopted thereunder and in accordance therewith), the issuance and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the General Corporation Law of the State of Delaware.

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

---

| |
|:---|
| Sincerely, |
| /s/ Latham & Watkins LLP |

---

## Exhibit 23.2

**Exhibit 23.2** 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of 4D Molecular Therapeutics, Inc. of our report dated March 18, 2026 relating to the financial statements, which appears in 4D Molecular Therapeutics, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025. We also consent to the reference to us under the heading "Experts"**** in such Registration Statement.

/s/ PricewaterhouseCoopers LLP

San Jose, California

March 18, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**4D Molecular Therapeutics, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common stock, $0.0001 par value per share | Other | 2880394 | $8.36 | $24080093.84 | 0.0001381 | $3325.47 |
| 2 | Equity | Common stock, $0.0001 par value per share | Other | 576079 | $7.11 | $4095921.69 | 0.0001381 | $565.65 |
| 3 | Equity | Common stock, $0.0001 par value per share | Other | 1000000 | $8.36 | $8360000.00 | 0.0001381 | $1154.52 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $36536015.53  |  | $5045.64  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $5045.64  |

---

 **Offering Note** <br>

<sup>1</sup> (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional shares of 4D Molecular Therapeutics, Inc.'s (the "Registrant") common stock that become issuable under the 2020 Incentive Award Plan (the "2020 Plan") by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant's receipt of consideration which would increase the number of outstanding shares of common stock. (2) Represents the additional shares of common stock available for future issuance under the Registrant's 2020 Plan resulting from an annual increase as of January 1, 2026. (3) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) of the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price for shares reserved for future issuance under the 2020 Plan are based on the average of the high and the low price of Registrant's Common Stock as reported on the Nasdaq Global Select Market on March 12, 2026, which was $8.36.

<sup>2</sup> (4) Pursuant to Rule 416(a) under the Securities Act, this registration statement shall also cover any additional shares of the Registrant's common stock that become issuable under the 2020 Employee Stock Purchase Plan by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant's receipt of consideration which would increase the number of outstanding shares of common stock. (5) Represents the additional shares of common stock available for future issuance under the Registrant's ESPP resulting from an annual increase as of January 1, 2026. (6) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) of the Securities Act on the basis of the average of the high and the low prices of common stock as reported on the Nasdaq Global Select Market on March 12, 2026, multiplied by 85%. Pursuant to the ESPP, the purchase price of the shares of common stock reserved for issuance thereunder will be at least 85% of the lower of the fair market value of a share of common stock on the applicable Grant Date or applicable Exercise Date.

<sup>3</sup> (7) Pursuant to Rule 416(a) under the Securities Act, this registration statement shall also cover any additional shares of the Registrant's common stock that become issuable under the 2025 Employment Inducement Award Plan (the "Inducement Plan") by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant's receipt of consideration which would increase the number of outstanding shares of common stock. (8) Represents the additional shares of common stock available for future issuance under the Registrant's Inducement Plan resulting from its amendment as of January 23, 2026. (9) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) and Rule 457(c) of the Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price for shares reserved for future issuance under the Inducement Plan are based on the average of the high and the low price of Registrant's Common Stock as reported on the Nasdaq Global Select Market on March 12, 2026, which was $8.36.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---